Docoh
Loading...

ANIX Anixa Biosciences

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body’s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Company profile

Ticker
ANIX
Exchange
Website
CEO
Amit Kumar
Employees
Incorporated
Location
Fiscal year end
Former names
COPYTELE INC, ITUS Corp
SEC CIK
IRS number
112622630

ANIX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Mar 21
17 Apr 21
31 Oct 21
Quarter (USD)
Jan 21 Oct 20 Jul 20 Apr 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Oct 20 Oct 19 Oct 18 Oct 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 11.98M 11.98M 11.98M 11.98M 11.98M 11.98M
Cash burn (monthly) (positive/no burn) (positive/no burn) 744.38K 798.46K 390.15K 452.64K
Cash used (since last report) n/a n/a 1.91M 2.05M 1M 1.16M
Cash remaining n/a n/a 10.07M 9.93M 10.98M 10.82M
Runway (months of cash) n/a n/a 13.5 12.4 28.1 23.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
25 Mar 21 Kumar Amit Common Stock Buy Aquire P No No 4.86 5,000 24.3K 277,000
25 Mar 21 Baskies Arnold M Common Stock Buy Aquire P No No 4.8 10,000 48K 51,000
25 Mar 21 Emily Gottschalk Common Stock Buy Aquire P No No 4.88 15,600 76.13K 15,600
25 Mar 21 Titterton Lewis H jr Common Stock Buy Aquire P No No 4.84 45,000 217.8K 865,326
3 Feb 21 Titterton Lewis H jr Common Stock Gift Dispose G No No 0 200,000 0 820,326

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: antigen, Assuming, country, domain, domestically, enrolled, enrollment, eventual, eventually, extracellular, growth, half, high, hope, hormone, identification, Imputed, infrastructure, joint, large, located, markedly, menopause, multiple, occurrence, outcome, ovary, patient, pharmaceutical, Phase, postmenopausal, prevent, preventative, prevention, profitable, Remdesivir, submission, tissue, trial, vector
Removed: acquisition, amortization, amortize, amortized, approval, artificial, assessment, blood, Boulevard, capitalize, commercialization, complaint, consistent, Corporation, derivative, detection, driven, economic, enable, exchanged, extensive, file, fully, intelligence, investment, leased, life, Los, manufactured, principally, putative, receivable, receiving, recent, reimbursement, restated, review, shareholder, state, strategic, subleased, submit, Subsequent, successfully, undergo, undiscounted, unvested, Wilshire, write, York